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Hepatitis C virus infection is a constant worldwide public health concern. The prevalence of HCV infection is higher in patients on 
chronic haemodialysis (HD) than in the general population. Despite the control of blood products, hepatitis C virus transmission is 
still being observed among patients undergoing dialysis. Detection systems for serum HCV antibodies are insensitive in the acute 
phase because of the long serological window. Direct detection of HCV depends on PCR test but this test is not suitable for routine 
screening.  The objective of this study was to determine prevalence of HCV, genotyping and  if  HCV core antigen test could be a 
better alternative to NAT techniques for the diagnosis of HCV infection during the window period and whether the sensitivity for 
antibody detection is preserved. We screened 159 patients on long-term dialysis by HVC antibodies test, PCR HCV-RNA and 
HCV core antigen test by commercial tests. The prevalence of HCV was 10.7% (17 patients) and genotype 4 was the most 
common one (64.7%). The sensitivity of HCV core antigen test was 94.1%, the specificity 100%, the positive predictive power 
100%, and the negative predictive power 97.9%. In conclusions; patients on maintenance HD in Yemen have a high prevalence of 
HCV infection comparing with general population; and genotype 4 is predominant. The performance of serological detection of 
HCV core antigen was better than that of HCV antibodies test and   may be an alternative to nucleic acid amplification technology 
(NAT) for routine monitoring of patients on chronic dialysis. 
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INTRODUCTION 
An estimated 143 million people (2%) worldwide are 





about 11 million new cases occurred
1
. It occurs most 
commonly in Africa and Central and East Asia.
2
 About 
167,000 deaths due to liver cancer and 326,000 deaths 
due to cirrhosis occurred in 2015 due to hepatitis C.
2
  
In Yemen HCV antibodies among general community 
showed a steady decline to less than 0.5%
3,4
, however  
among  HCV risk groups such as  dental workers  and 
public health center workers, it was 5.5% and 11.5% 
respectively
5,6
.  Limited information is available among 
patients for dialysis in Yemen. HCV infection is more 
common among patients for dialysis than in healthy 
populations worldwide. The Dialysis Outcomes and 
Practice Patterns Study (DOPPS) reported a general 
prevalence of 13.5 percent among adult hemodialysis 
patients randomly selected from 308 dialysis services 
in developed countries (France, Germany, Italy, Japan, 
Spain, the United Kingdom, and the United States)
7
. A 
study from Australia and New Zealand
8
 in HD patients 
(n=23,046) reported an independent and significant 
association between anti-HCV positive serologic status 
and all-cause mortality over a 10-year follow up (HR, 
1.25, 95% CI 1.07–1.46, P=0.004). Regardless of the 
control of blood products, HCV transmission is 
stationary being observed among HD patients. HCV 
infection diagnosis is usually rooted in the detection of 
an anti-HCV antibody, while it goes undetected in the 
first 4–6 weeks of infection (so-called window period). 
Furthermore, patients positive for anti-HCV antibody 
include both those who are actively infected and those 
Hanish et al.                                                                        Universal Journal of Pharmaceutical Research                           
 ISSN: 2456-8058                                                           15                                     CODEN (USA): UJPRA3               
who have recovered from infection
9
.  Kidney Disease 
Improving Global Outcomes (KDIGO) clinical practice 
guidelines for the prevention, diagnosis, evaluation, 
and treatment of hepatitis C in chronic kidney disease
10 
recommended the use of nucleic acid amplification 
technology (NAT). A quantitative HCV core antigen 
(HCVcAg) test has been developed for the 
confirmation of viremia in patients with hepatitis C. 
This test can detect total nucleo-capsid core antigen 
whose sequence is highly conserved across HCV 
genotypes.  A number of studies in the general 
population have highlighted the importance of HCV 
core antigen detection as an alternative to NAT for 
early diagnosis of infection, as direct marker of viral 
replication in chronic phase of infection and as relevant 
marker for predicting and monitoring the response to 
therapy
11
. Few studies exist about the efficacy of HCV 
core antigen test in patients on chronic HD in the early 
diagnosis of HCV infection
12-14
.  The objective of this 
study was to determine prevalence of HCV, genotyping 
and  if  HCV core antigen test could be better an 
alternative to NAT techniques for the diagnosis of 
HCV infection during the window period and whether 
the sensitivity for antibody detection is preserved.   
 
SUBJECTS AND METHODS 
The study was performed in the haemodialysis units of 
Al-Thorah hospital. A total of 159 patients were 
enrolled in this cross sectional study in 2016; patients 
gave informed consent and thus the whole patient 
population were investigated. All patients underwent 
chronic haemodialysis treatment for end stage renal 
disease during the study period.   The laboratory tests 
were conducted in Al-Awalagy Medical laboratory. 
Anti-HCV antibody was measured by a third 
generation commercial ELISA (Enzymun-Test Anti-
HCV; Boehringer Mannheim, Germany). The third 
generation assay detects antibodies for three viral 
antigens (c22-3, c200, and NS5). HCV-RNA and viral 
genotype were assessed using PCR.  All tests were 
carried out and interpreted strictly in accordance with 
the manufacturer's instructions.  
Statistical Analysis 
The performance of the HCV core antigens and 
antibodies HCV test were done by comparing to HCV-
RNA PCR test. The following parameters were 
calculated: sensitivity%, Specificity%, false positive% 
(FP), false negative% (FN), positive predictive value 
(PPV);  and negative predictive value (NPV). Gender 
and age group's which are possible associated risk 
factors for HCV infection were assessed. The data were 
examined in a case-control study format. For HCV, 
persons with evidence of previous or current infection 
with HCV were matched up with those who were HCV 
negative.  
Ethical Consideration 
Ethical clearance for the study was taken from the 
Faculty of Medicine and Health Sciences Research 
Review Committee. Informed Consent was taken from 





Table 1shows the prevalence rate of HCV ribonucleic 
acid (RNA), and associated odds ratio for different sex 
and age of a sample of hemodialysis patients in Sana'a 
city. The prevalence rate of HCV among HD patients 
was 10.7%, for male patients was 14.3%, higher than 
8.7% for female patients. When age was considered, 
there was an increasing trend of HCV infection with 
increasing age. The genotype distribution in 17 HCV-
positive patients is shown in Table 2. Overall, HCV 
genotype 4 was the most predominant genotype 
(64.7%) followed by genotype 1a and 1b (29.4%) and 
2a (5.9%). Table 3 shows the prevalence rate of 
different HCV markers in 159 haemodialysis patients 
in Sana'a city. Seventeen HD patients were HCV 
ribonucleic acid (RNA) positive, 14 HD patients were 
HCV antibodies positive and 16 HD patients were 
HCV core proteins positive. Table 4 shows the 
performance of HCV antibodies test  and HCV Core 
protein test compared to HCV ribonucleic acid (RNA) 
among haemodialysis patients in Sana'a city. The 
sensitivity of HCV core antigen test was 94.1%, the 
specificity 100%, the positive predictive power 100%, 
the negative predictive power 97.9%, false positive rate 
0.0% and false negative rate 5.9%. However less 
reliable results were found for HCV antibodies test in 
which the sensitivity of HCV antibodies test was 
70.6%, the specificity 98.9%, the positive predictive 
power 100%, the negative predictive power 97.9% 
false positive rate 1.41% and false negative rate 29.4%.  
 
DISCUSSION 
Information on the prevalence of HCV in the general 
population and in the various high risk groups such as 
HD patients, prevalence of genotypes and evolution of 
tests used for screening HCV are important in the 
prevention and control HBV infections.  Unfortunately, 
there is little information available on these topics, 
particularly from Middle East countries and more 
specifically from Yemen. HCV infection continues to 
be the most frequently recognized cause of liver 
damage in CKD patients
15
. Although a severe clinical 
course of HCV-related liver disease seems unusual in 
most HD patients and cirrhosis is an infrequent event 
among dialysis patients, longitudinal studies have 
found an independent and significant relationship 
between anti-HCV antibody positivity and reduced 
patient survival
16,17
. The Dialysis Outcomes and 
Practice Patterns Study (DOPPS) on HD patients in 
three continent
18
 had reported an independent and 
significant association between positive anti-HCV 
antibody and mortality risk (adjusted relative risk, 
1.17; P < 0.0159). Fabrizi et al.
19
 showed that HCV-
seropositive HD patients had higher rates of liver 
disease-related death than their sero-negative matching 
parts, but that cardiovascular and infectious disease 
related mortality rates were similar
19
. Ohsawa et al. 
showed that seropositivity for anti-HCVcAg is 
independently associated with increased all-cause, 
cardiovascular, and liver disease related mortality in 
HD patients
20
. In the current study in Yemen the 
prevalence rate of HCV among HD patients was 
10.7%, (male rate=14.3%, female rate=8.7%). This 
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result is indicative that HCV infection is more common 





The current result also is 
slightly lower than the Dialysis Outcomes and Practice 
Patterns Study (DOPPS) which reported an overall 
prevalence of 13.5% among adult hemodialysis 






In addition, our study results show that HCV genotype 
4 is the predominant genotype (64.7%) among Yemeni 
patients followed by 1a and 1b (29.4%) and 2a (5.9%). 
This data is similar to that reported in Middle East 
countries, and previously in the Yemen; where 
genotype 4 is predominant
4, 21-24
.  
 It is important to diagnose a hepatitis C virus infection 
in the acute phase in order to reduce the incidence of 





Biochemical evaluation of HCV infection in 
patients with CKD is inaccurate. Serum 
aminotransferase values are typically lower in dialysis 
patients than the non-uremic populations
26
.  Thus we 
carried out this study to evaluate the performance of 
HCV antibodies test and HCV Core protein test 
comparing to HCV ribonucleic acid (RNA) among our 
haemodialysis patients (Table 4).  The sensitivity of 
HCV core antigen test was 94.1%, the specificity 
100%, the positive predictive power 100%, the 
negative predictive power 97.9%, false positive rate 
0.0% and false negative rate 5.9%. However less 
reliable results were found for HCV antibodies test in 
which the sensitivity of HCV antibodies test was 
70.6%, the specificity 98.9%, the positive predictive 
power 100%, the negative predictive power 97.9% 
false positive rate 1.41% and false negative rate 29.4%. 
Our results is similar to that reported previously in 
which detection systems for serum HCV antibodies are 
insensitive in the acute phase because of the long 
serological window
7
.  Also, the direct detection of 
HCV depends on NAT techniques with several 
problems: frequent unavailability, considerable skill 
requirement, limited reproducibility, and overall 
important costs. HCV detection by PCR-RNA, 
although widely accepted as a gold standard test in the 
diagnosis of HCV infection in CKD patients, it is not 
suitable for routine screening
7
. Thus from our results 
HCV core antigen quantification assay has   proved 
useful for an early diagnosis of HCV infection in 
community-based and in dialysis populations. Also, 
HCV core antigen may be an alternative to HCV-RNA 
detection, since no subjects, who were negative for 
HCV core antigen, were positive for HCV-RNA (false 
negative=0.0%). Our result is similar to that reported in 
a large population-based cohort studies by Ohsawa et 
al. 
27
; and by Kato et al.
28
 in which no subjects, who 
were negative for HCV core antigen, were positive for 
HCV-RNA; also Ohsawa et al.
27
 and Kato et al.
28
 
suggests that detection of HCV core antigen combined 
with anti-HCV antibody is useful in predicting long-
term survival prognosis of persistent HCV infection in 
HD patients. 
Finally, from our experience HCV core antigen test is 
both a cost-effective (a single sample has a 40$ charge 
for PCR HCVRNA and a 5$ charge for HCV core 
antigen test) and a less labour-intensive alternative to 
NAT tests. These features make it a routine assay 
useful for chronic dialysis treatment patients. 
 
CONCLUSION 
Patients on maintenance HD in Yemen have a high 
incidence and prevalence of HCV infection and 
genotype 4 is the predominant one. Serological 
detection of HCV core antigen may be an alternative to 
NAT techniques for routine monitoring of patients on 
chronic dialysis towards the prevention of HCV spread. 
HCV core antigen is an accurate marker for early 
identification of HCV infection; it can improve 
virological monitoring and integrate the diagnosis of 
acute hepatitis C in dialysis population. The minimal 
cost and its easiness make this assay useful for routine 
long-term dialysis treatment patients. Furthermore, 
screening for HCV antibodies alone does not exclude 
infection with HCV. 
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Table 1: The prevalence rate of HCV ribonucleic acid (RNA), and associated odds ratio for different sex and 




















Male n=56 8 14.3 1.7 0.6-4.7 1.16 0.27 
Female n = 103 9 8.7 0.67 0.21-2.2 0.57 0.45 
Age groups 
< 20 Yrs n=13 1 7.7 0.73 0.11-5.2 0.09 0.76 
20 - 29 Yrs 
n=35 
2 5.7 0.5 0.1-2.4 0.41 0.33 
30 - 39 Yrs 
n=23 
2 8.7 0.83 0.12-4.3 0.06 0.81 
40 - 49 Yrs 
n=22 
3 13.6 1.5 0.3-6.4 0.36 0.54 
> 49 Yrs n=66 9 13.6 1.6 0.6-4.6 1.02 0.31 
n= 159 
crude rate 
17 10.7     
OR-Odds ratio ≥ 1 is at risk of infection, CI-Confidence intervals; χ2-Chi-square ≥ 3.83 is significant 
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Table 2: The prevalence of different HCV genotyping among HCV HD patients, Sana'a city, Yemen 
Genotypes Number Percentage 
Genotype 1a+1b 5 29.4 
Genotype 2a 1 5.9 
Genotype 4 11 64.7 
Genotype 3a 0 0 
Genotype 5 0 0 
Genotype 6 0 0 
Total 17 100 
 
 





Positive      Negative 
Total 
HCV antibodies 
Positive 12 2 14 
Negative 5 140 145 
HCV core proteins 
Positive 16 0 16 
Negative 1 142 143 
Total 17 142 159 
 
 
Table 4: The performance of HCV antibodies test and HCV Core protein test comparing to HCV ribonucleic 
acid (RNA) among haemodialysis patients in Sana'a city 
Evaluated tests Sensitivity Specify% FP % FN% PPV% NPV% 
ELISA HCV antibodies 70.6 98.9 1.41 29.4 85.7 96.6 
ELISA HCV core protein 
(core antigen) 
94.1 100 0.0 5.9 100 97.9 
Sensitivity: Probability that test will be positive, given the patient is disease. Specify: Probability that the test will be negative, given the patient is 
disease free.  FP=false positive: Probability that test will be positive; known the patient is disease free.  FN= false negative: Probability that test 
will be negative, known the patient is diseased. PPV= positive predictive value: Probability that a patient is diseased, given a positive test.  
NPV= negative predictive value: Probability that a patient disease free, given a negative test. 
 
 
 
 
 
 
 
